Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Multisite, Randomized, Double-Masked, Well-Controlled Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections: The QUELL Study

NCT07456826 is registered in ClinicalTrials.gov with Harrow Inc as lead sponsor.

NCT NCT07456826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07456826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Multisite, Randomized, Double-Masked, Well-Controlled Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections: The QUELL Study
Lead sponsor
Harrow Inc
Phase
Phase 4
Overall status
Enrolling by invitation
Start date
March 31, 2026
Completion date
August 31, 2026
Enrollment
236 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration (amd), diabetic macular edema (dme), diabetic retinopathy (dr), retinal vein occlusion